Methadone Retention Pilot Included Substantial Benzodiazepine Prescribing

Psychiatric complexity and prescribed co-exposure need to be described separately from program retention.

What the publication shows

A seventy-patient second-chance methadone program accepted people facing discharge elsewhere. Benzodiazepine prescriptions were more frequent among participants receiving disability benefits than among those without those benefits. Those subgroups did not have a clear difference in six-month or one-year retention. Methadone dose was an important predictor in the analysis.

Limits of the evidence

The pilot was small, observational and conducted at one clinic with unusual retention-focused policies. Prescription indications were unavailable, and clinic rules influenced outcomes. The findings do not establish that benzodiazepine co-prescribing was safe, beneficial or responsible for retention.

Application to expert review

When reviewing opioid treatment, distinguish prescribed benzodiazepines, nonprescribed use and toxicology results. Avoid interpreting continued engagement in care as proof of pharmacological safety, or treating disability status as a direct measure of medication impairment.

Source and related reading

Source: Publication PMC9669697. The case-review applications above are interpretive analysis.